429 results on '"Bailer, Robert T"'
Search Results
2. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants
3. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
4. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
5. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.
6. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
7. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
8. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
9. Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
10. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
11. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
12. Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry
13. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
14. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody
15. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial
16. Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
17. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
18. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge
19. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
20. Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
21. Supplemental Materials for Safety and Immunogenicity of Chimpanzee Adenovirus Vector Ebola Vaccine
22. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma
23. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals
24. Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect
25. Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire
26. Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization
27. Chimpanzee Adenovirus Vector Ebola Vaccine
28. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface
29. Structure and immune recognition of trimeric pre-fusion HIV-1 Env
30. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
31. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
32. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial
33. Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
34. Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
35. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
36. Isolation of human monoclonal antibodies from peripheral blood B cells
37. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
38. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
39. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
40. Immune Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
41. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
42. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
43. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection
44. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
45. Safety and immunogenicity of a gag-pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
46. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
47. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax ® challenge in vaccinia-naïve and vaccinia-immune individuals
48. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients
49. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability
50. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.